Novartis Heart Drug Fails to Stop Attacks

The drug worked on paper. It did not stop heart attacks.

Novartis announced Friday that its Phase 3 trial for pelacarsen failed to reduce the risk of cardiovascular events like heart attacks and strokes. The news hit hard. Investors pulled back fast. The company’s share price dropped more than 7% in after-market trading.

For the thousands of people who signed up for the Lp(a)HORIZON study, the result lands in a quiet, heavy way. These were patients with established heart disease and high levels of lipoprotein(a), a stubborn, inherited risk factor that diet and standard cholesterol drugs barely touch. They took their injections every four weeks. They kept taking their statins and blood pressure pills. They waited. They hoped this new option would lower the chance of another cardiac event.

Pelacarsen did what it was designed to do in the lab. It reduced levels of lipoprotein(a), often called Lp(a), by a large margin. For years, high Lp(a) has been tied to greater heart risk. Many doctors believed that lowering it would help protect patients already on guideline-directed care. That belief made this trial one of the most watched in cardiovascular medicine.

It did not play out that way.

In the study of 8,323 participants, pelacarsen did not cut the combined risk of cardiovascular death, non-fatal heart attack, non-fatal stroke, or urgent coronary revascularization requiring hospitalization compared to placebo. The drug lowered the biomarker. It did not lower the events that matter most to patients and families.

“These are not the results we hoped for,” said Shreeram Aradhye, Novartis’ Chief Medical Officer. He added that the data “may help inform future approaches to cardiovascular risk management.”

That sentence is careful. It is also a shield.

I have sat in small exam rooms with people told their Lp(a) was high and that nothing they could do at home would change it. They heard the word “genetic” and felt the floor drop. A new drug that targeted that exact number felt like a door opening. Now that door closes for this therapy in this broad group. The science moves on. The person in the chair does not get that time back.

There are other Lp(a)-lowering drugs in late-stage testing from companies like Amgen and Eli Lilly. Some use different mechanisms, such as small interfering RNA, and aim for even deeper reductions. Their outcomes trials are still running. This failure does not end the field. It does, however, force a harder look at whether lowering Lp(a) alone is enough when patients are already on strong standard therapy.

The financial hit was immediate. U.S.-listed Novartis stock slipped about 7% after hours. Ionis Pharmaceuticals, which partnered with Novartis on pelacarsen, also fell sharply. Analysts will rewrite models. Pipeline slides will shift. For a company, this is a setback to be managed. For a patient counting on a new option, it is a delay with no clear end date.

What remains unknown is whether any subgroup benefited. Novartis said full results will be presented at a medical meeting. It is possible that people with the very highest Lp(a) levels saw some protection. It is possible the benefit was too small to show up in a trial of this size. Those details matter. They will shape how doctors talk to patients with high Lp(a) in the months ahead.

For now, the standard of care stands. Statins, blood pressure control, smoking cessation, and lifestyle changes remain the backbone. Some patients with extremely high Lp(a) and recurrent events still turn to lipoprotein apheresis, a time-consuming procedure that filters the blood. That path is not scalable for millions. It is a stopgap, not a solution.

The disappointment here is not just about one drug. It is about the gap between a clean lab signal and a messy human outcome. A number on a blood test went down. Heart attacks did not. That gap is where trust erodes. It is where patients start to wonder how many more years they must wait for something that actually changes their odds.

Novartis will present the full data set soon. Regulators will review it. Other companies will watch closely as their own trials mature. The science will advance, as it always does.

In the meantime, there is a person somewhere opening a letter about trial results, or sitting in a clinic hearing the news from a doctor. They did the right thing. They showed up. They took the shots. They believed lowering that one number would help keep them alive.

That belief was not foolish. It was human.